Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
11-14 October, 2025
Aus. Peptide Conferenc...Aus. Peptide Conference
Not Confirmed
Not Confirmed
12-17 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
11-14 October, 2025
Aus. Peptide Conferenc...Aus. Peptide Conference
Industry Trade Show
Not Confirmed
12-17 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-are-building-capabilities-to-stay-ahead-of-the-curve-and-align-with-future-needs-of-global-healthcare
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
03 Sep 2025
// PHARMAWEB
https://www.pharmiweb.com/press-release/2025-09-03/aldeyra-therapeutics-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference
28 Aug 2025
// PHARMAWEB
https://www.pharmiweb.com/press-release/2025-08-28/aldeyra-therapeutics-receives-orphan-designation-from-the-european-medicines-agency-for-adx-2191-for
19 Aug 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250819317013/en/Aldeyra-Therapeutics-Receives-Fast-Track-Designation-for-ADX2191-for-the-Treatment-of-Retinitis-Pigmentosa
06 Aug 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250806352225/en/Aldeyra-Therapeutics-to-Participate-in-the-H.C.-Wainwright-5th-Annual-Ophthalmology-Virtual-Conference
17 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250717410973/en/Aldeyra-Therapeutics-Announces-FDA-Acceptance-for-Review-of-Reproxalap-New-Drug-Application-for-the-Treatment-of-Dry-Eye-Disease
26 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250626651175/en/Aldeyra-Therapeutics-Receives-Special-Protocol-Assessment-Agreement-Letter-from-the-U.S.-Food-and-Drug-Administration-for-ADX-2191-for-the-Treatment-of-Primary-Vitreoretinal-Lymphoma
Details:
ADX-2191 (methotrexate intravitreal injection) is being investigated as the potential treatment of specific rare retinal diseases, including primary vitreoretinal lymphoma and retinitis pigmentosa.
Lead Product(s): Methotrexate,Inapplicable
Therapeutic Area: Oncology Brand Name: ADX-2191
Study Phase: IND EnablingProduct Type: Cytotoxic Drug
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2025
Lead Product(s) : Methotrexate,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EMA Grants Orphan Status To Aldeyra’s ADX-2191 For Rare Lymphomas
Details : ADX-2191 (methotrexate intravitreal injection) is being investigated as the potential treatment of specific rare retinal diseases, including primary vitreoretinal lymphoma and retinitis pigmentosa.
Product Name : ADX-2191
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 28, 2025
Details:
ADX-102 (reproxalap) is a first-in-class small-molecule modulator of RASP being developed for the treatment of dry eye disease and allergic conjunctivitis.
Lead Product(s): Reproxalap,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 05, 2025
Lead Product(s) : Reproxalap,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reproxalap Hits Phase 3 Endpoint for Dry Eye, NDA Resubmission Planned
Details : ADX-102 (reproxalap) is a first-in-class small-molecule modulator of RASP being developed for the treatment of dry eye disease and allergic conjunctivitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 05, 2025
Details:
ADX-102 (reproxalap) is an investigational new drug candidate, it is a first-in-class small-molecule inhibitor of RASP, It is being evaluated for the treatment of dry eye disease.
Lead Product(s): Reproxalap,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2025
Lead Product(s) : Reproxalap,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aldeyra Therapeutics Receives Complete Response Letter from FDA for the Reproxalap
Details : ADX-102 (reproxalap) is an investigational new drug candidate, it is a first-in-class small-molecule inhibitor of RASP, It is being evaluated for the treatment of dry eye disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2025
Details:
AbbVie has the option for co-exclusive license for ADX-102 (reproxalap), a first-in-class small-molecule modulator of RASP, for dry eye disease, in the United States.
Lead Product(s): Reproxalap,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 18, 2024
Lead Product(s) : Reproxalap,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Agreement
Aldeyra Announces FDA Review of Reproxalap for Dry Eye, Expands AbbVie Agreement
Details : AbbVie has the option for co-exclusive license for ADX-102 (reproxalap), a first-in-class small-molecule modulator of RASP, for dry eye disease, in the United States.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 18, 2024
Details:
ADX-629 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis, Alcoholic.
Lead Product(s): ADX-629,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 12, 2024
Lead Product(s) : ADX-629,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADX-629 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis, Alcoholic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 12, 2024
Details:
ADX-102 (reproxalap) is an investigational new drug candidate, it is a first-in-class small-molecule inhibitor of RASP, It is being evaluated for the treatment of dry eye disease.
Lead Product(s): Reproxalap,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 03, 2024
Lead Product(s) : Reproxalap,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aldeyra Therapeutics Resubmits Reproxalap NDA For Treatment of Dry Eye Disease
Details : ADX-102 (reproxalap) is an investigational new drug candidate, it is a first-in-class small-molecule inhibitor of RASP, It is being evaluated for the treatment of dry eye disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 03, 2024
Details:
ADX-102 (reproxalap) is an investigational new drug candidate, it is a first-in-class small-molecule inhibitor of RASP, It is being evaluated for the treatment of dry eye disease.
Lead Product(s): Reproxalap,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 08, 2024
Lead Product(s) : Reproxalap,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aldeyra Achieves Primary Endpoint in Phase 3 Trial of Reproxalap for Dry Eye Disease
Details : ADX-102 (reproxalap) is an investigational new drug candidate, it is a first-in-class small-molecule inhibitor of RASP, It is being evaluated for the treatment of dry eye disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 08, 2024
Details:
Reproxalap is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Lead Product(s): Reproxalap,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 10, 2024
Lead Product(s) : Reproxalap,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Details : Reproxalap is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 10, 2024
Details:
ADX-102 (reproxalap) is an investigational new drug candidate, it is a first-in-class small-molecule inhibitor of RASP, It is being evaluated for the treatment of dry eye disease.
Lead Product(s): Reproxalap,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2024
Lead Product(s) : Reproxalap,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aldeyra Completes Enrollment in Phase 3 Trial of Reproxalap in Dry Eye Disease
Details : ADX-102 (reproxalap) is an investigational new drug candidate, it is a first-in-class small-molecule inhibitor of RASP, It is being evaluated for the treatment of dry eye disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 13, 2024
Details:
Reproxalap is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Lead Product(s): Reproxalap,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 22, 2024
Lead Product(s) : Reproxalap,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Details : Reproxalap is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 22, 2024
ABOUT THIS PAGE